PDCD1 and non-small cell lung carcinoma: Unknown status.To assess the safety of combining FMT with PD-1/PD-L1 Monoclonal Antibodies in the treatment of advanced NSCLC, and analyze the impact of FMT on intestinal flora and immunophenotype of patients.